United Bank VA Has $228,000 Position in Gilead Sciences, Inc. (GILD)

United Bank VA held its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,216 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. United Bank VA’s holdings in Gilead Sciences were worth $228,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Penserra Capital Management LLC raised its stake in shares of Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Gilead Sciences in the 2nd quarter worth $147,000. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Gilead Sciences by 29.3% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 480 shares in the last quarter. Rowland & Co. Investment Counsel ADV bought a new stake in shares of Gilead Sciences in the 2nd quarter worth $153,000. Finally, Capstone Investment Advisors Netherlands B.V. bought a new stake in shares of Gilead Sciences in the 2nd quarter worth $172,000. 76.23% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences, Inc. (NASDAQ GILD) opened at $74.34 on Friday. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $97,080.00, a price-to-earnings ratio of 7.94, a PEG ratio of -1.27 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter in the previous year, the company posted $2.75 earnings per share. Gilead Sciences’s revenue for the quarter was down 13.2% compared to the same quarter last year. analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.80%. Gilead Sciences’s dividend payout ratio is 23.66%.

In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. Insiders have sold 494,999 shares of company stock worth $37,404,139 in the last quarter. 1.30% of the stock is currently owned by corporate insiders.

A number of analysts have recently commented on GILD shares. Argus raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Thursday, August 31st. Deutsche Bank reissued a “buy” rating and issued a $81.00 price objective on shares of Gilead Sciences in a research note on Thursday, August 31st. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective on the stock in a research note on Friday, October 13th. Credit Suisse Group reissued an “outperform” rating and issued a $85.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a research note on Tuesday, August 29th. Finally, Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $85.11.

WARNING: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2017/12/15/united-bank-va-has-228000-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

What are top analysts saying about Gilead Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit